相似文献
1
Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy.
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S228-31. doi: 10.5489/cuaj.1203.
2
A systematic overview of chemotherapy effects in urothelial bladder cancer.
Acta Oncol. 2001;40(2-3):371-90. doi: 10.1080/02841860151116466.
3
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Cancer. 2013 Aug 15;119(16):3012-9. doi: 10.1002/cncr.28146. Epub 2013 May 29.
4
Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Urol Oncol. 2020 Nov;38(11):850.e1-850.e7. doi: 10.1016/j.urolonc.2020.06.014. Epub 2020 Jul 18.
5
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
6
Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery.
Transl Androl Urol. 2016 Oct;5(5):735-744. doi: 10.21037/tau.2016.08.23.
7
[Surgical treatment of metastatic urothelial carcinoma of the bladder: Review of the Cancer Committee of the French Association of Urology].
Prog Urol. 2013 Oct;23(12):951-7. doi: 10.1016/j.purol.2013.03.004. Epub 2013 Apr 17.
8
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3.
9
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21.
10
[Clinical efficacy of methotrexate, vinblastine, doxorubicin and cisplatin adjuvant chemotherapy following radical surgery for locally invasive urothelial cancers: long-term results].
Nihon Hinyokika Gakkai Zasshi. 1995 May;86(5):1016-21. doi: 10.5980/jpnjurol1989.86.1016.
引用本文的文献
1
Patients with Metastatic or Locally Advanced Bladder Cancer Not Undergoing Systemic Oncological Treatment-Characteristics and Long-Term Outcome in a Single-Center Danish Cohort.
Cancers (Basel). 2025 Mar 25;17(7):1105. doi: 10.3390/cancers17071105.
2
Rectal Metastasis Causing Rectal Constriction From High-Grade Urothelial Carcinoma.
Cureus. 2025 Feb 21;17(2):e79416. doi: 10.7759/cureus.79416. eCollection 2025 Feb.
3
Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
Int J Urol. 2024 Jul;31(7):730-738. doi: 10.1111/iju.15450. Epub 2024 Mar 12.
4
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
BMC Cancer. 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2.
5
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.
Int J Mol Sci. 2022 Oct 11;23(20):12119. doi: 10.3390/ijms232012119.
6
EUS-guided fine needle aspiration provides an open view for duodenal obstruction caused by urothelial carcinoma: a case report.
BMC Gastroenterol. 2022 Aug 8;22(1):376. doi: 10.1186/s12876-022-02452-1.
7
Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience.
Cent European J Urol. 2019;72(2):113-120. doi: 10.5173/ceju.2019.1902. Epub 2019 Apr 24.
8
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
J Med Econ. 2019 Jul;22(7):662-670. doi: 10.1080/13696998.2019.1591424. Epub 2019 Mar 25.
9
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.
Urol Oncol. 2018 Jan;36(1):9.e11-9.e17. doi: 10.1016/j.urolonc.2017.09.009. Epub 2017 Oct 5.
10
An uncommon cause of gastric outlet obstruction: A case report.
Medicine (Baltimore). 2017 Jun;96(23):e7059. doi: 10.1097/MD.0000000000007059.
本文引用的文献
1
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.
Eur Urol. 2009 Apr;55(4):815-25. doi: 10.1016/j.eururo.2009.01.002. Epub 2009 Jan 13.
2
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
Eur Urol. 2009 Jun;55(6):1293-9. doi: 10.1016/j.eururo.2008.11.039. Epub 2008 Nov 29.
3
Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
Eur Urol. 2007 Oct;52(4):1106-13. doi: 10.1016/j.eururo.2007.02.052. Epub 2007 Mar 6.
4
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.
J Urol. 2004 Jan;171(1):145-8. doi: 10.1097/01.ju.0000099823.60465.e6.
5
The systemic treatment of advanced and metastatic bladder cancer.
Lancet Oncol. 2003 Aug;4(8):489-97. doi: 10.1016/s1470-2045(03)01168-9.
6
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
J Urol. 2003 Jun;169(6):2113-7. doi: 10.1097/01.ju.0000067601.29966.4a.
7
After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?
Eur Urol. 2002 Oct;42(4):344-9; discussion 349. doi: 10.1016/s0302-2838(02)00320-2.
8
9
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
J Clin Oncol. 2001 May 15;19(10):2638-46. doi: 10.1200/JCO.2001.19.10.2638.
10
Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy.
J Urol. 2001 Jan;165(1):62-4; discussion 64. doi: 10.1097/00005392-200101000-00015.
Zotero 插件